Form 4: Amicus Therapeutics Director Michael Kelly Granted Significant Equity Awards

Amicus Therapeutics, Inc. Director Michael Aaron Kelly was granted 20,414 Restricted Stock Units and 74,872 stock options on June 5, 2025, as part of his compensation.

Summary

• Director Michael Aaron Kelly of Amicus Therapeutics, Inc. received a grant of 20,414 Restricted Stock Units (RSUs) on June 5, 2025.
• Each RSU is equivalent to one share of Amicus common stock and will vest in full on the one-year anniversary of the grant date, payable in common stock.
• Additionally, Mr. Kelly was granted 74,872 stock options with an exercise price of $5.96 per share.
• These stock options will vest 100% on the one-year anniversary of the grant date (June 5, 2026) and are set to expire on June 5, 2035.
• Following these transactions, Mr. Kelly beneficially owns 72,468 shares of common stock and 74,872 stock options directly.

Sentiment

Score: 7

Explanation: The filing indicates a standard equity grant to a director, which is a positive sign of aligning management incentives with shareholder interests, without any negative implications.

Positives

• The grant of RSUs and stock options aligns the director's interests with long-term shareholder value.
• Equity compensation is a common practice to incentivize directors and retain talent, reflecting standard corporate governance practices.

Future Outlook

NA

Industry Context

This Form 4 filing details a standard equity compensation grant to a director in the biotechnology/pharmaceutical industry. Such grants are common practice to align executive and director incentives with long-term company performance and shareholder interests, reflecting a typical compensation structure for board members in publicly traded companies.

Related Party Transactions

• The grant of equity awards to a director is considered a related party transaction, as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with long-term shareholder value, potentially leading to better governance and performance.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The Restricted Stock Units are expected to vest on June 5, 2026.
• The Stock Options are expected to vest and become exercisable on June 5, 2026.

Key Dates

Recommendation

Keywords

Amicus Therapeutics, FOLD, SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSUs, Stock Options, Director Compensation, Beneficial Ownership